Status:
COMPLETED
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
Lead Sponsor:
Aurinia Pharmaceuticals Inc.
Collaborating Sponsors:
United BioSource, LLC
Conditions:
Lupus Nephritis
Eligibility:
All Genders
18+ years
Brief Summary
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
Detailed Description
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the United States (US). This registry is intended to b...
Eligibility Criteria
Inclusion
- Lupus nephritis (LN) confirmed by biopsy
- Initiating or have initiated treatment with commercial LUPKYNIS as per US approved Prescribing Information (PI)
- Written informed consent
Exclusion
- \- Off-label use (Use of LUPKYNIS outside of the FDA-approved US Prescribing Information)
Key Trial Info
Start Date :
April 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2025
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT05337124
Start Date
April 5 2022
End Date
January 31 2025
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 00-05
South Gate, California, United States, 90280